Login to Your Account


DUBLIN – The European biotechnology sector enjoyed a period of sustained investor appetite in 2017, reflecting its ongoing ability to tap into global equity markets in order to fund development of its pipeline. Total investment reached $6.85 billion in disclosed transactions involving drug development firms.

DUBLIN – Enterome SA raised €32 million (US$38.6 million) in a series D financing round and secured access to another €40 million through a loan facility with the European Investment Bank (EIB), which gives it more than enough firepower to complete proof-of-concept trials of its lead drug candidates in Crohn's disease and in cancer.

DUBLIN – The EMA's Committee for Human Medicinal Products (CHMP) closed out 2017 with recommendations for three new drug approvals and for one new biosimilar, along with positive recommendations for five products approved under the generic, hybrid or informed consent pathways, plus two line extensions.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: